Literature DB >> 20140141

Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths.

Stephen V Faraone.   

Abstract

Medications used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among agents are hindered by the absence of head-to-head clinical trials. By using meta-analysis, we sought to compare the efficacy of these medications for the symptoms of ADHD. We analyzed published literature on the pharmacotherapy of ADHD to describe the variability of drug-placebo effect sizes and conducted a literature search to identify double-blind, placebo-controlled studies of youths with ADHD that were published after 1979. Meta-analysis regression was used to assess the influence of the medication type on drug effects. We also assessed for publication bias.Thirty-two trials met our criteria and were included in this meta-analysis. These trials involved 16 drugs using 20 different outcome measures of ADHD behaviors. The effect sizes for immediate-release stimulants and long-acting stimulants were similar and were greater than the effect sizes for non-stimulants. There was no evidence of publication bias.Although nearly all of the ADHD medications had significant effects, we found substantial variability. When translated into the costs of treating large numbers of patients, these effect sizes have implications for formulary medication choices.

Entities:  

Keywords:  ADHD; efficacy; medications

Year:  2009        PMID: 20140141      PMCID: PMC2810184     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  46 in total

1.  Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.

Authors:  Jason E Kemner; H Lynn Starr; Patrick E Ciccone; Christa G Hooper-Wood; R Steve Crockett
Journal:  Adv Ther       Date:  2005 Sep-Oct       Impact factor: 3.845

Review 2.  Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents.

Authors:  T E Wilens; J Biederman; R J Baldessarini; B Geller; D Schleifer; T J Spencer; B Birmaher; A Goldblatt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-11       Impact factor: 8.829

3.  Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study.

Authors:  T A Rugino; T C Copley
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

Review 4.  Attention-deficit hyperactivity disorder.

Authors:  Joseph Biederman; Stephen V Faraone
Journal:  Lancet       Date:  2005 Jul 16-22       Impact factor: 79.321

5.  A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Authors:  Laurence L Greenhill; Robert L Findling; James M Swanson
Journal:  Pediatrics       Date:  2002-03       Impact factor: 7.124

6.  Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.

Authors:  Kristina Secnik; Andrine Swensen; Maureen J Lage
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; Raun D Melmed; Anil Patel; Keith McBurnett; Jennifer Konow; Andrew Lyne; Noreen Scherer
Journal:  Pediatrics       Date:  2008-01       Impact factor: 7.124

8.  A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder.

Authors:  Gregory A Fabiano; William E Pelham; Erika K Coles; Elizabeth M Gnagy; Andrea Chronis-Tuscano; Briannon C O'Connor
Journal:  Clin Psychol Rev       Date:  2008-11-11

9.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

10.  Attention-deficit/hyperactivity disorder: increased costs for patients and their families.

Authors:  Andrine R Swensen; Howard G Birnbaum; Kristina Secnik; Maryna Marynchenko; Paul Greenberg; Ami Claxton
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-12       Impact factor: 8.829

View more
  46 in total

1.  Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Authors:  Benjamin L Handen; Michael G Aman; L Eugene Arnold; Susan L Hyman; Rameshwari V Tumuluru; Luc Lecavalier; Patricia Corbett-Dick; Xueliang Pan; Jill A Hollway; Kristin A Buchan-Page; Laura B Silverman; Nicole V Brown; Robert R Rice; Jessica Hellings; Daniel W Mruzek; Sarah McAuliffe-Bellin; Elizabeth A Hurt; Melissa M Ryan; Lynne Levato; Tristram Smith
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-09-03       Impact factor: 8.829

2.  Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.

Authors:  Tanya E Froehlich; Jason Fogler; William J Barbaresi; Nada A Elsayed; Steven W Evans; Eugenia Chan
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

3.  Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.

Authors:  Bjørn E Ramtvedt; Henning S Aabech; Kjetil Sundet
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-03-25       Impact factor: 2.576

4.  Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.

Authors:  Matej Stuhec; Igor Locatelli
Journal:  Int J Clin Pharm       Date:  2018-02-21

Review 5.  The neurobiological basis of ADHD.

Authors:  Paolo Curatolo; Elisa D'Agati; Romina Moavero
Journal:  Ital J Pediatr       Date:  2010-12-22       Impact factor: 2.638

6.  Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study.

Authors:  Heather A Gordon; Julia J Rucklidge; Neville M Blampied; Jeanette M Johnstone
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-12       Impact factor: 2.576

7.  Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.

Authors:  Mark A Stein; Irwin Waldman; Jeffrey Newcorn; Jeffrey Bishop; Rick Kittles; Edwin H Cook
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-09       Impact factor: 2.576

8.  Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review.

Authors:  Jeffery N Epstein; Margaret D Weiss
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-29

9.  Stimulant Medications and Cognition, Behavior and Quality of Life in Children and Youth with HIV.

Authors:  Patricia A Sirois; Lisa Aaron; Grace Montepiedra; Deborah A Pearson; Suad Kapetanovic; Paige L Williams; Patricia A Garvie; Molly L Nozyce; Kathleen Malee; Sharon L Nichols; Betsy L Kammerer; Wendy G Mitchell; Mark Mintz; James M Oleske
Journal:  Pediatr Infect Dis J       Date:  2016-01       Impact factor: 2.129

10.  Parental etiological explanations and longitudinal medication use for youths with attention deficit hyperactivity disorder.

Authors:  May Yeh; Gregory A Aarons; Judy Ho; Laurel K Leslie; Kristen McCabe; Katherine Tsai; Richard Hough
Journal:  Adm Policy Ment Health       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.